不同腔内方法治疗股腘动脉中重度钙化病变的荟萃分析
该系统评价与荟萃分析纳入13项研究,评估腔内治疗股腘动脉中重度钙化外周动脉疾病(PAD)的总体疗效,汇总12个月一期通畅率为83.8%、免于临床驱动靶病变血运重建(f-CD-TLR)率为90.7%;按治疗策略分层的描述性亚组估计存在差异,但作者强调不能视为优劣排序。
要点
- 腔内治疗股腘动脉中重度钙化病变的12个月一期通畅率汇总为83.8%。
- 12个月f-CD-TLR汇总为90.7%,敏感性分析显示结论稳定。
- 亚组估计仅作描述,不能作为不同治疗策略优劣比较的证据。
核心结论
- 腔内治疗在股腘动脉中重度钙化病变中可获得可接受的短期疗效。
- 不同治疗策略的报告结局存在差异,但因缺乏头对头比较,不能据此判断优劣。
研究设计与样本
- 系统检索PubMed、Scopus、Embase、Cochrane Central Register和Web of Science Core Collection,自建库至2026年7月。
- 最终纳入13项研究,主要结局为12个月一期通畅率和f-CD-TLR。
主要发现
- 总体分析显示腔内治疗后12个月一期通畅率汇总效应量为83.8%。
- 总体分析显示f-CD-TLR汇总效应量为90.7%。
- 敏感性分析证实结论高度稳定。
- 亚组描述性估计:支架策略一期通畅率83.0%、f-CD-TLR 87.12%。
- 亚组描述性估计:斑块旋切策略为86.66%和96.58%,血管内碎石策略为82.75%和89.2%。
关键数值与推荐
- 12个月一期通畅率汇总效应量为83.8%。
- 12个月f-CD-TLR汇总效应量为90.7%。
- 支架策略亚组:一期通畅率83.0%,f-CD-TLR 87.12%。
- 斑块旋切策略亚组:一期通畅率86.66%,f-CD-TLR 96.58%。
- 血管内碎石策略亚组:一期通畅率82.75%,f-CD-TLR 89.2%。
临床怎么用
- 可将汇总的12个月一期通畅率和f-CD-TLR作为股腘动脉中重度钙化病变腔内治疗疗效的参考基准。
- 选择具体治疗策略时应结合病变特点与设备可及性,不宜依据本亚组描述性估计进行优劣排序。
局限性
- 缺乏不同器械间的头对头比较,亚组估计仅作描述性解读。
- 未检测到显著发表偏倚,但研究数较少的亚组中该评估的可靠性可能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To systematically evaluate the overall clinical outcomes of endovascular treatment in patients with peripheral artery disease (PAD) presenting with moderate-to-severe calcification of the femoropopliteal artery, and to descriptively summarize reported outcomes across different endovascular treatment strategies. METHODS: A systematic search was conducted in PubMed, Scopus, Embase, the Cochrane Central Register, and Web of Science Core Collection from database inception to July 2026 to identify studies related to endovascular treatment in patients with moderate-to-severe calcified PAD of the femoropopliteal artery. The primary outcome measures included the 12-month primary patency rate and freedom from clinically driven target lesion revascularization (f-CD-TLR). RESULTS: A total of 13 studies were finally included. The overall analysis showed that the pooled effect size of the 12-month primary patency rate after endovascular treatment was 83.8%, and the pooled effect size of f-CD-TLR was 90.7%. Sensitivity analysis confirmed the high stability of the conclusions. Subgroup analyses, stratified by treatment strategy and presented in a neutral technology-based order, showed the following descriptive estimates: stent-based strategies (primary patency: 83.0%; f-CD-TLR: 87.12%), atherectomy-based strategies (86.66% and 96.58%), and intravascular lithotripsy-based strategies (82.75% and 89.2%). These subgroup estimates should be interpreted descriptively and should not be considered comparative rankings or evidence of superiority of one treatment strategy over another. No significant publication bias was detected; however, the reliability of these assessments may be limited in subgroups with a small number of studies. CONCLUSION: Endovascular treatment can achieve acceptable short-term outcomes in patients with moderate-to-severe calcified femoropopliteal artery disease. Descriptive subgroup analyses demonstrated variation in reported outcomes across treatment strategies. Given the limited availability of head-to-head comparisons, further high-quality comparative studies between different devices are warranted to better define their relative efficacy.
引用
- Wang B, Wu H, Wu W, et al. Clinical Efficacy of Different Endovascular Approaches in Femoropopliteal Artery Disease with Moderate-to-Severe Calcification: A Meta-Analysis. Ann Vasc Surg. 2026. PMID: 42562226. doi:10.1016/j.avsg.2026.07.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。